Irinotecan and radiation in combined-modality therapy for solid tumors

Hak Choy, Rob Macrae

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Irinotecan (CPT-11, Camptosar) is a camptothecin derivative that is thought to exert its cytotoxic effects by targeting topoisomerase I. It is believed that irinotecan stabilizes a DNA-topoisomerase I cleavable complex, and that interactions between this complex and the replication machinery may lead to cell death. There is a significant volume of in vitro and in vivo data demonstrating that irinotecan acts as a radiosensitizer. The exact mechanism of this radiosensitization is currently unknown. The increasing amount of data demonstrating improved outcomes with concurrent chemoradiation treatment of malignancies like lung cancer and head and neck cancer provide impetus for pursuing the addition of other drugs as radiosensitizers to improve local control further. Irinotecan is undergoing early clinical trials in the combined-modality setting in several disease sites. This article will provide an overview of the current status of irinotecan used concurrently with radiotherapy in the treatment of a variety of solid tumors.

Original languageEnglish (US)
Pages (from-to)22-28
Number of pages7
JournalOncology
Volume15
Issue number7 SUPPL. 8
StatePublished - 2001

Fingerprint

irinotecan
Combined Modality Therapy
Radiation
Neoplasms
Type I DNA Topoisomerase
Head and Neck Neoplasms
Camptothecin

ASJC Scopus subject areas

  • Oncology

Cite this

Irinotecan and radiation in combined-modality therapy for solid tumors. / Choy, Hak; Macrae, Rob.

In: Oncology, Vol. 15, No. 7 SUPPL. 8, 2001, p. 22-28.

Research output: Contribution to journalArticle

Choy, H & Macrae, R 2001, 'Irinotecan and radiation in combined-modality therapy for solid tumors', Oncology, vol. 15, no. 7 SUPPL. 8, pp. 22-28.
Choy, Hak ; Macrae, Rob. / Irinotecan and radiation in combined-modality therapy for solid tumors. In: Oncology. 2001 ; Vol. 15, No. 7 SUPPL. 8. pp. 22-28.
@article{d2046e25e60a47a4979f1fe23225cfc9,
title = "Irinotecan and radiation in combined-modality therapy for solid tumors",
abstract = "Irinotecan (CPT-11, Camptosar) is a camptothecin derivative that is thought to exert its cytotoxic effects by targeting topoisomerase I. It is believed that irinotecan stabilizes a DNA-topoisomerase I cleavable complex, and that interactions between this complex and the replication machinery may lead to cell death. There is a significant volume of in vitro and in vivo data demonstrating that irinotecan acts as a radiosensitizer. The exact mechanism of this radiosensitization is currently unknown. The increasing amount of data demonstrating improved outcomes with concurrent chemoradiation treatment of malignancies like lung cancer and head and neck cancer provide impetus for pursuing the addition of other drugs as radiosensitizers to improve local control further. Irinotecan is undergoing early clinical trials in the combined-modality setting in several disease sites. This article will provide an overview of the current status of irinotecan used concurrently with radiotherapy in the treatment of a variety of solid tumors.",
author = "Hak Choy and Rob Macrae",
year = "2001",
language = "English (US)",
volume = "15",
pages = "22--28",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7 SUPPL. 8",

}

TY - JOUR

T1 - Irinotecan and radiation in combined-modality therapy for solid tumors

AU - Choy, Hak

AU - Macrae, Rob

PY - 2001

Y1 - 2001

N2 - Irinotecan (CPT-11, Camptosar) is a camptothecin derivative that is thought to exert its cytotoxic effects by targeting topoisomerase I. It is believed that irinotecan stabilizes a DNA-topoisomerase I cleavable complex, and that interactions between this complex and the replication machinery may lead to cell death. There is a significant volume of in vitro and in vivo data demonstrating that irinotecan acts as a radiosensitizer. The exact mechanism of this radiosensitization is currently unknown. The increasing amount of data demonstrating improved outcomes with concurrent chemoradiation treatment of malignancies like lung cancer and head and neck cancer provide impetus for pursuing the addition of other drugs as radiosensitizers to improve local control further. Irinotecan is undergoing early clinical trials in the combined-modality setting in several disease sites. This article will provide an overview of the current status of irinotecan used concurrently with radiotherapy in the treatment of a variety of solid tumors.

AB - Irinotecan (CPT-11, Camptosar) is a camptothecin derivative that is thought to exert its cytotoxic effects by targeting topoisomerase I. It is believed that irinotecan stabilizes a DNA-topoisomerase I cleavable complex, and that interactions between this complex and the replication machinery may lead to cell death. There is a significant volume of in vitro and in vivo data demonstrating that irinotecan acts as a radiosensitizer. The exact mechanism of this radiosensitization is currently unknown. The increasing amount of data demonstrating improved outcomes with concurrent chemoradiation treatment of malignancies like lung cancer and head and neck cancer provide impetus for pursuing the addition of other drugs as radiosensitizers to improve local control further. Irinotecan is undergoing early clinical trials in the combined-modality setting in several disease sites. This article will provide an overview of the current status of irinotecan used concurrently with radiotherapy in the treatment of a variety of solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=0035406843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035406843&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 22

EP - 28

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7 SUPPL. 8

ER -